Clinical Trials Logo

Filter by:
NCT ID: NCT03805607 Active, not recruiting - Postoperative Pain Clinical Trials

IV Ketorolac on Platelet Function Post-Cesarean Delivery

KetoPltAgg
Start date: January 18, 2021
Phase: Phase 4
Study type: Interventional

Cesarean delivery has become the most common surgical procedure in the US. Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to improve the quality of post-cesarean analgesia and markedly reduce opioid consumption. The effect of NSAIDs on healthy volunteers results in inhibition of platelet aggregation and prolonged bleeding time. However, in the obstetric population, the presence and degree of platelet inhibition after NSAID exposure is less clear. The investigators plan to use Platelet Aggregometry and Thromboelastography (TEG) to evaluate the effect of ketorolac on platelets.

NCT ID: NCT03805594 Active, not recruiting - Clinical trials for Prostate Adenocarcinoma

177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Start date: May 10, 2019
Phase: Phase 1
Study type: Interventional

This phase Ib trial studies the dose and schedule of 177Lu-PSMA-617 and pembrolizumab in treating patients with castration-resistant prostate cancer that has spread to other places in the body. 177Lu-PSMA-617 carries a radioactive component which attached to the prostate specific membrane antigen (PSMA) receptor found on tumor cells. Its radiation component destroys the tumor cell. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving 177Lu-PSMA-617 and pembrolizumab may work better at treating prostate cancer.

NCT ID: NCT03805217 Active, not recruiting - Hypotension Clinical Trials

Hypotension Prediction Index Study (HPI Study)

Start date: May 16, 2019
Phase:
Study type: Observational

A prospective, single-arm, open-label, multicenter post-approval study to determine whether the use of the Acumen HPI Software to guide intraoperative hemodynamic management in non-cardiac surgery reduces the duration of intraoperative hypotension below a threshold of Mean Arterial Pressure (MAP)

NCT ID: NCT03804502 Active, not recruiting - Dry Eye Syndromes Clinical Trials

Pilot Study of TearCare System - Long-Term Extension

Start date: December 17, 2018
Phase: N/A
Study type: Interventional

The objective of the study is to evaluate the long-term clinical utility, safety, and effectiveness of re-treatment with the TearCareā„¢ System in adult patients with dry eye syndrome who had previously been treated with the TearCare System.

NCT ID: NCT03803904 Active, not recruiting - Aging Clinical Trials

Aerobic Exercise and Cerebrovascular Function

Start date: April 1, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

This proposal will evaluate two brain health measures, cerebrovascular perfusion and cerebrovascular reactivity (CVR), before and after a proven, interval-based, aerobic exercise intervention in older Veterans. The hypothesis is that the 12-week aerobic exercise intervention (Spin) will increase perfusion and improve CVR in brain regions susceptible to age-related decline. This information will inform the impact of exercise on cerebrovascular health which is known to be negatively impacted in aging and implicated in the development of neurogenerative disease. This information will also aid the investigators' continued efforts of clinical implementation of evidence-based exercise interventions in the local Atlanta VA and surround region.

NCT ID: NCT03803696 Active, not recruiting - Sexual Dysfunction Clinical Trials

Multimodal Sexual Dysfunction Intervention In HCT

Start date: February 1, 2019
Phase: N/A
Study type: Interventional

This research study is evaluating the impact of an intervention to improve sexual function in stem cell transplant survivors on participants' sexual function, quality of life, and mood. It is expected that about 120 people who have undergone a stem cell transplant will take part in this research study.

NCT ID: NCT03802981 Active, not recruiting - Clinical trials for Multiple Ground Glass Opacities (GGOs)

A Registry for Patients With Multifocal Ground Glass Opacities (GGOs)

Start date: January 9, 2019
Phase:
Study type: Observational [Patient Registry]

The purpose of this registry study is to actively monitor people with GGOs and collect information about them, so that investigators can learn more about these lesions and about the risk of developing lung cancer in study participants whose GGOs are being monitored in the active surveillance program.

NCT ID: NCT03801395 Active, not recruiting - Clinical trials for Primary Ciliary Dyskinesia

PCD New Gene Discovery

Start date: January 7, 2019
Phase:
Study type: Observational

This is a new gene discovery program for individuals with PCD who do not have a specific genetic etiology identified. Research procedures involve a single blood draw from the affected individual and from unaffected family members in an effort to identify new genetic targets.

NCT ID: NCT03800602 Active, not recruiting - Clinical trials for Colorectal Cancer Metastatic

Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer

Start date: January 15, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well nivolumab and metformin work in treating patients with microsatellite stable (MSS) stage IV colorectal cancer that has not responded to previous treatment. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Metformin is an antidiabetic drug that and may reduce the risk of colorectal cancer development in patients. Giving nivolumab and metformin may work better in treating patients with refractory microsatellite metastatic colorectal cancer.

NCT ID: NCT03800134 Active, not recruiting - Clinical trials for Non-Small Cell Lung Cancer

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

AEGEAN
Start date: December 6, 2018
Phase: Phase 3
Study type: Interventional

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of pathological complete response.